Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 22;12(1):e003077.
doi: 10.1136/openhrt-2024-003077.

Effects of 1-year exercise in patients with atrial fibrillation: study protocol for the Norwegian Exercise in Atrial Fibrillation (NEXAF) randomised controlled trial

Bjarne M Nes  1   2 , Jon Magne Letnes  3   2 , Kristin Espolin Johnson  3 , Andreas Berg Sellevold  3   2 , Rune Byrkjeland  4   5 , Fedelix Phetogo Brown  6 , Turid Follestad  7 , Håvard Dalen  3   2   8 , Ulrik Wisløff  3 , Maja-Lisa Løchen  6   9 , Arnljot Tveit  4   10 , Bente Morseth  11 , Marius Myrstad  4 , Jan Pål Loennechen  3   2 ; NEXAF consortium; The NEXAF consortium
Collaborators, Affiliations

Effects of 1-year exercise in patients with atrial fibrillation: study protocol for the Norwegian Exercise in Atrial Fibrillation (NEXAF) randomised controlled trial

Bjarne M Nes et al. Open Heart. .

Abstract

Introduction: Atrial fibrillation is the most prevalent sustained arrhythmia worldwide and is expected to increase substantially within the coming years. Although lifestyle changes and risk factor modification are now acknowledged as central components of atrial fibrillation management, the effects of exercise on disease-specific outcomes are still not extensively documented due to few high-quality randomised trials. The primary objective of the Norwegian Exercise in Atrial Fibrillation Trial (NEXAF) is to assess the effects of exercise over 12 months on key clinical and patient-reported outcomes in previously inactive patients with atrial fibrillation.

Methods and analysis: NEXAF is a multicentre, two-arm, randomised controlled trial inviting patients 18-80 years with a confirmed diagnosis of paroxysmal or persistent atrial fibrillation. Eligible patients are randomised 1:1 to either a combined supervised and eHealth-based exercise intervention or usual care for 12 months. The primary outcomes are total time in atrial fibrillation measured by insertable cardiac monitors, and disease-specific quality of life measured by the Atrial Fibrillation Effect on Quality-of-Life questionnaire.

Ethics and dissemination: Ethical approval was obtained from the Regional Ethics Committee in Mid-Norway in April 2021 (ID 213848).

Trial registration number: NCT05164718.

Keywords: Atrial Fibrillation; Cardiac Rehabilitation; Outcome Assessment, Health Care.

PubMed Disclaimer

Conflict of interest statement

Competing interests: M-LL has received lecture fees from Bayer, Sanofi and BMS/Pfizer. MM has received lecture fees from Astra Zeneca, Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, MSD and Pfizer. HD reports institutional partnership with GE Healthcare through Centre for Innovative Ultrasound Solutions funded by the Research Council of Norway and lecture fees from Bayer AG, Boehringer Ingelheim, Pfizer, Amgen, Astra Zeneca and GE HealthCare. The remaining authors have nothing to declare.

Figures

Figure 1
Figure 1. Brief overview of the NEXAF trial design. NEXAF, Norwegian Exercise in Atrial Fibrillation Trial.
See this image and copyright information in PMC

References

    1. Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Int J Stroke. 2021;16:217–21. doi: 10.1177/1747493019897870. - DOI - PubMed
    1. Martin SS, Aday AW, Almarzooq ZI, et al. 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation. 2024;149:e347–913. doi: 10.1161/CIR.0000000000001209. - DOI - PubMed
    1. Becher N, Metzner A, Toennis T, et al. Atrial fibrillation burden: a new outcome predictor and therapeutic target. Eur Heart J. 2024;45:2824–38. doi: 10.1093/eurheartj/ehae373. - DOI - PMC - PubMed
    1. Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) Eur Heart J. 2024;45:3314–414. doi: 10.1093/eurheartj/ehae176. - DOI - PubMed
    1. Visseren FLJ, et al. ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC) Eur Heart J. 2021;42:3227–337. doi: 10.1093/eurheartj/ehab484. - DOI - PubMed

Publication types

Associated data